Companies Prothena Corp Public Ltd Co
Prothena Corp Public (PRTA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Prothena Corp Public Ltd Co’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 10 peer CEOs
CEO pay, last three years
- $7,043,826FY2023
- $7,230,959FY2024
- $5,896,045FY2025
CEO total pay was $5,896,045 in fiscal 2025, down from $7,230,959 in fiscal 2024.
FY2025: salary $692,973 · bonus $0 · stock awards $961,800 · option awards $3,809,738
Executives and directors
Chad Swanson · Chief Development OfficerGene Kinney · CEOBrandon Smith · COOTran Nguyen · CFOWagner Zago · Chief Scientific OfficerDaniel G. Welch · Chair of the BoardDennis J. Selkoe · Independent DirectorHelen S. Kim · Independent DirectorLars G. Ekman · Independent DirectorPaula K. Cobb · Former director (through FY2025)Richard T. Collier · Independent DirectorShane M. Cooke · Independent DirectorWilliam H. Dunn Jr · Independent Director
Frequently asked questions
Who was the highest-paid executive at Prothena Corp Public Ltd Co in fiscal 2025?
As disclosed, Gene Kinney (President and Chief Executive Officer) was the highest-paid executive at Prothena Corp Public Ltd Co in fiscal 2025, with total compensation of $5,896,045.
How does Prothena Corp Public Ltd Co's chief executive pay compare to its disclosed peer group?
As disclosed, Gene Kinney's total compensation ranked at the 50th percentile of Prothena Corp Public Ltd Co's disclosed peer group.
What is Prothena Corp Public Ltd Co's CEO-to-median employee pay ratio?
As disclosed, Prothena Corp Public Ltd Co's CEO-to-median employee pay ratio was 14:1.
How did shareholders vote on Prothena Corp Public Ltd Co's executive compensation?
As disclosed, 96.58% of shareholders supported Prothena Corp Public Ltd Co's executive compensation in the latest say-on-pay vote.
How much does Prothena Corp Public Ltd Co spend in total on board compensation for fiscal 2025?
As disclosed, Prothena Corp Public Ltd Co reported total board compensation of $645,815 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gene Kinney | $692,973 | $0 | $961,800 | $3,809,738 | $415,784 | $0 | $15,750 | $5,896,045 |
| President and Chief Executive Officer | ||||||||
| Brandon Smith | 540,713 | 0 | 893,100 | 1,092,125 | 270,356 | 0 | 15,750 | 2,812,044 |
| Chief Operating Officer | ||||||||
| Tran Nguyen | 600,389 | 0 | 652,650 | 1,092,125 | 300,195 | 0 | 15,750 | 2,661,109 |
| Chief Strategy Officer and Chief Financial Officer | ||||||||
| Chad Swanson | 516,667 | 0 | 583,950 | 1,092,125 | 206,667 | 0 | 15,750 | 2,415,159 |
| Chief Development Officer | ||||||||
| Wagner Zago | 514,221 | 0 | 583,950 | 1,092,125 | 205,689 | 0 | 15,750 | 2,411,735 |
| Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Gene Kinney | $5,896,045 | $7,230,959 | $7,043,826 | ↓ −1,334,914 |
| Brandon Smith | 2,812,044 | 2,503,988 | 2,627,937 | ↑ +308,056 |
| Tran Nguyen | 2,661,109 | 2,593,636 | 2,700,292 | ↑ +67,473 |
| Chad Swanson | 2,415,159 | — | — | — |
| Wagner Zago | 2,411,735 | 2,412,307 | — | ↓ −572 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation programs are designed to align executive pay outcomes with the Company's performance. We believe that our named executive officers' fiscal year 2025 compensation was aligned with the Company's performance for the year and with the Company's go-forward strategy.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Tran Nguyen | OPTION | 2025-03-05 | — | — | 107,500 | — | $1,092,125 |
| Gene Kinney | OPTION | 2025-03-05 | — | — | 375,000 | — | 3,809,738 |
| Chad Swanson | OPTION | 2025-03-05 | — | — | 107,500 | — | 1,092,125 |
| Wagner Zago | OPTION | 2025-03-05 | — | — | 107,500 | — | 1,092,125 |
| Brandon Smith | OPTION | 2025-03-05 | — | — | 107,500 | — | 1,092,125 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Tran Nguyen | $0 | $0 | $1,092,125 | 0.0% |
| Gene Kinney | 0 | 0 | 3,809,738 | 0.0% |
| Chad Swanson | 0 | 0 | 1,092,125 | 0.0% |
| Wagner Zago | 0 | 0 | 1,092,125 | 0.0% |
| Brandon Smith | 0 | 0 | 1,092,125 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Tran Nguyen | Option | 3,542 | 32.45 | — |
| Brandon Smith | Option | 3,542 | 32.45 | — |
| Wagner Zago | Option | 3,542 | 32.45 | — |
| Gene Kinney | Option | 10,417 | 32.45 | — |
| Chad Swanson | Option | 14,625 | 30.3 | — |
| Tran Nguyen | Option | 15,000 | 52.97 | — |
| Brandon Smith | Option | 15,000 | 52.97 | — |
| Wagner Zago | Option | 15,000 | 52.97 | — |
| Chad Swanson | Option | 24,792 | 53.67 | — |
| Chad Swanson | Option | 28,334 | 16.65 | — |
| Tran Nguyen | Option | 46,042 | 30.3 | — |
| Brandon Smith | Option | 46,042 | 30.3 | — |
| Wagner Zago | Option | 46,042 | 30.3 | — |
| Gene Kinney | Option | 48,438 | 52.97 | — |
| Chad Swanson | RSU | 85,000 | — | 811,750 |
| Wagner Zago | RSU | 85,000 | — | 811,750 |
| Tran Nguyen | RSU | 95,000 | — | 907,250 |
| Tran Nguyen | Option | 107,500 | 14.95 | — |
| Brandon Smith | Option | 107,500 | 14.95 | — |
| Chad Swanson | Option | 107,500 | 14.95 | — |
| Wagner Zago | Option | 107,500 | 14.95 | — |
| Brandon Smith | RSU | 130,000 | — | 1,241,500 |
| Gene Kinney | RSU | 140,000 | — | 1,337,000 |
| Gene Kinney | Option | 166,292 | 30.3 | — |
| Gene Kinney | Option | 375,000 | 14.95 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel G. WelchIndependent · Board Chair · Compensation Committee | $97,089 | $0 | $95,831 | $0 | $0 | $192,920 |
| Shane M. CookeIndependent · Audit Committee (Chair) · Compensation Committee (Chair) | 87,500 | — | 95,831 | — | 0 | 183,331 |
| Paula K. CobbIndependent · Departed during FY | 85,000 | — | 95,831 | — | 0 | 180,831 |
| Richard T. CollierIndependent · Audit Committee · Nominating and Corporate Governance Committee (Chair) | 80,000 | — | 95,831 | — | 0 | 175,831 |
| Lars G. EkmanIndependent · Audit Committee · Research and Development Committee (Chair) | 80,000 | — | 95,831 | — | 0 | 175,831 |
| Dennis J. SelkoeIndependent · Compensation Committee · Research and Development Committee | 70,000 | — | 95,831 | — | 6,500 | 172,331 |
| William H. Dunn JrIndependent · Nominating and Corporate Governance · Research and Development | 74,726 | — | 95,831 | — | 0 | 170,557 |
| Helen S. KimIndependent · Nominating and Corporate Governance Committee · Not standing for re-election | 65,000 | — | 95,831 | — | 0 | 160,831 |
| Gene G. KinneyEmployee director · Nominating and Corporate Governance | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $639,315 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $6,500 |
| Total cost of the board | $645,815 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Prothena Corp Public as a peer
Companies that benchmark against PRTA
8 companies name PRTA as a compensation peer
The list of companies that name PRTA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AVXL Anavex Life SciencesRCUS Arcus BiosciencesCLDX Celldex TherapeuticsDNLI Denali TherapeuticsREPL Replimune GroupBHVN Biohaven Ltd.AXSM AxsomeNMRA Neumora TherapeuticsITCI Intra-CellularSAGE Sage Therapeutics
Peer reciprocity
The companies Prothena Corp Public Ltd Co names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Biohaven Ltd. | 2025 | Vlad Coric | $920,400 | $2,202,480 | $9,900,043 | $0 | $13,500,438 |
| 2 | Axsome | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 3 | Intra-Cellular | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 4 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 5 | Sage Therapeutics | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 6 | Prothena Corp Public Ltd Co | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 7 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 8 | Celldex Therapeutics | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 9 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 10 | Neumora Therapeutics | 2025 | Paul Berns | 700,000 | 0 | 3,326,181 | 504,000 | 4,562,461 |
| 11 | Anavex Life Sciences | 2025 | Christopher Missling | 723,485 | 0 | 3,083,000 | 0 | 3,959,085 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Prothena Corp Public Ltd Co | 100% | not disclosed | not disclosed | Pay Governance LLC |
| Anavex Life Sciences | not disclosed | Option 100 | not disclosed | not disclosed |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Axsome | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Biohaven Ltd. | not disclosed | not disclosed | not disclosed | Aon |
| Celldex Therapeutics | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| Intra-Cellular | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Neumora Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Sage Therapeutics | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-14 | 32,303,076 | 1,145,400 | 1,204,899 | 96.58% | Passed |
| 2023 | 2023-05-16 | 45,196,711 | 358,628 | 1,184,436 | 99.21% | Passed |
| 2022 | 2022-05-17 | 41,665,912 | 337,890 | 38,603 | 99.2% | Passed |
| 2021 | 2021-05-18 | 27,615,035 | 6,734,179 | 22,125 | 80.39% | Passed |
| 2020 | 2020-05-19 | 32,956,571 | 1,573,036 | 25,863 | 95.44% | Passed |
| 2019 | 2019-05-21 | 22,460,377 | 10,616,209 | 879,957 | 67.9% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-14 | 96.58%a |
| 2023 | 2023-05-16 | 99.21%b |
| 2022 | 2022-05-17 | 99.2%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 14 : 1 |
|---|---|
| CEO total compensation | $5,896,045 |
| Median employee compensation | $417,917 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Anne Evans Kingston | Chief Strategy Officer | 2026-04-10 | A | 100,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| William H. Dunn Jr | Director | 2026-05-15 | A | 27,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel G. Welch | Director | 2026-05-15 | A | 27,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane M. Cooke | Director | 2026-05-15 | A | 27,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lars G. Ekman | Director | 2026-05-15 | A | 27,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard T. Collier | Director | 2026-05-15 | A | 27,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dennis J. Selkoe | Director | 2026-05-15 | A | 27,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-05-22 | A | 100,000 | 10 | 981,300 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-06-02 | A | 50,000 | 9 | 471,300 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-06-04 | A | 50,000 | 9 | 465,295 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-06-11 | A | 125,000 | 8 | 1,021,225 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-06-15 | D | 325,000 | 0 | 0 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-06-16 | A | 20,000 | 8 | 157,990 | Common | Form 4 ↗ |
| Brandon Smith | Chief Operating Officer | 2026-07-28 | A | 78,000 | — | — | Common | Form 4 ↗ |
| Chad Swanson | Chief Development Officer | 2026-07-28 | D | 40,800 | 9 | 349,248 | Common | Form 4 ↗ |
| Brandon Smith | Chief Operating Officer | 2026-07-28 | D | 78,000 | 9 | 667,680 | Common | Form 4 ↗ |
| Chad Swanson | Chief Development Officer | 2026-07-28 | A | 51,000 | — | — | Common | Form 4 ↗ |
| Anne Evans Kingston | Chief Strategy Officer | 2026-07-28 | D | 3,498 | 9 | 29,943 | Common | Form 4 ↗ |
| Gene G. Kinney | Director | 2026-07-28 | A | 84,000 | — | — | Common | Form 4 ↗ |
| Brandon Smith | Chief Operating Officer | 2026-07-28 | D | 78,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chad Swanson | Chief Development Officer | 2026-07-28 | D | 51,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chad Swanson | Chief Development Officer | 2026-07-28 | D | 3,467 | 9 | 29,678 | Common | Form 4 ↗ |
| Karin L. Walker | Chief Accounting Officer | 2026-07-28 | D | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karin L. Walker | Chief Accounting Officer | 2026-07-28 | D | 15,000 | 9 | 128,400 | Common | Form 4 ↗ |
| Karin L. Walker | Chief Accounting Officer | 2026-07-28 | A | 15,000 | — | — | Common | Form 4 ↗ |
| Wagner Zago | Chief Scientific Officer | 2026-07-28 | D | 51,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wagner Zago | Chief Scientific Officer | 2026-07-28 | A | 51,000 | — | — | Common | Form 4 ↗ |
| Michael John Isaacs | General Counsel & Company Sec. | 2026-07-28 | D | 4,694 | 9 | 40,181 | Common | Form 4 ↗ |
| Gene G. Kinney | Director | 2026-07-28 | D | 84,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gene G. Kinney | Director | 2026-07-28 | D | 84,000 | 9 | 719,040 | Common | Form 4 ↗ |
| Tran Nguyen | Chief Strategy Officer and CFO | 2026-07-28 | D | 57,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tran Nguyen | Chief Strategy Officer and CFO | 2026-07-28 | D | 57,000 | 9 | 487,920 | Common | Form 4 ↗ |
| Tran Nguyen | Chief Strategy Officer and CFO | 2026-07-28 | A | 57,000 | — | — | Common | Form 4 ↗ |
| Wagner Zago | Chief Scientific Officer | 2026-07-28 | D | 51,000 | 9 | 436,560 | Common | Form 4 ↗ |
| Michael John Isaacs | General Counsel & Company Sec. | 2026-07-29 | D | 8,386 | 8 | 71,055 | Common, open-market sale | Form 4 ↗ |
| Anne Evans Kingston | Chief Strategy Officer | 2026-07-29 | D | 7,662 | 8 | 64,919 | Common, open-market sale | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-08-07 | A | 3,500 | 9 | 30,167 | Common, indirect | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-08-07 | A | 34,000 | 9 | 293,053 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-08-10 | A | 251,553 | 0 | 0 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-08-17 | A | 336,000 | 0 | 0 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-08-18 | D | 627,553 | 0 | 0 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-08-20 | A | 50,000 | 9 | 439,430 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-09-02 | A | 27,000 | 9 | 255,739 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-09-18 | A | 100,000 | 8 | 843,460 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-09-28 | A | 103,500 | 9 | 889,872 | Common, indirect | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-09-29 | A | 162,000 | 9 | 1,405,674 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-02 | A | 100,000 | 9 | 857,240 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-07 | A | 125,000 | 8 | 1,050,150 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-08 | A | 90,000 | 9 | 770,904 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-13 | A | 100,000 | 8 | 835,480 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-14 | A | 10,000 | 8 | 84,569 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-22 | A | 100,000 | 8 | 818,520 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-23 | A | 50,000 | 8 | 403,525 | Common | Form 4 ↗ |
| William P. Scully | Greater-than-10% holder | 2026-10-27 | A | 566,444 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (92 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Gene Kinney. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 5,896,045. View filing ↗
- Section 01, Brandon Smith. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,812,044. View filing ↗
- Section 01, Tran Nguyen. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,661,109. View filing ↗
- Section 01, Chad Swanson. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,415,159. View filing ↗
- Section 01, Wagner Zago. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table - Fiscal Year 2025” · page 36. As printed: 2,411,735. View filing ↗
- Section 03, Tran Nguyen OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Gene Kinney OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Chad Swanson OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Wagner Zago OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Brandon Smith OPTION. DEF 14A, filed 2026-03-27. Section “Grants of Plan-Based Awards - Fiscal Year 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-27. Section “CEO Pay Ratio”. As printed: 14 : 1. View filing ↗
- Section 08, Daniel G. Welch. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 192,920. View filing ↗
- Section 08, Shane M. Cooke. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 183,331. View filing ↗
- Section 08, Paula K. Cobb. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 180,831. View filing ↗
- Section 08, Richard T. Collier. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 175,831. View filing ↗
- Section 08, Lars G. Ekman. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 175,831. View filing ↗
- Section 08, Dennis J. Selkoe. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 172,331. View filing ↗
- Section 08, William H. Dunn Jr. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 170,557. View filing ↗
- Section 08, Helen S. Kim. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 160,831. View filing ↗
- Section 08, Gene G. Kinney. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Anne Evans Kingston 2026-04-10. Form 4, filed 2026-04-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William H. Dunn Jr 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel G. Welch 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane M. Cooke 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lars G. Ekman 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard T. Collier 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis J. Selkoe 2026-05-15. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-05-22. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandon Smith 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chad Swanson 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandon Smith 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chad Swanson 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anne Evans Kingston 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gene G. Kinney 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandon Smith 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chad Swanson 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chad Swanson 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karin L. Walker 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karin L. Walker 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karin L. Walker 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wagner Zago 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wagner Zago 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael John Isaacs 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gene G. Kinney 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gene G. Kinney 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tran Nguyen 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tran Nguyen 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tran Nguyen 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wagner Zago 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael John Isaacs 2026-07-29. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anne Evans Kingston 2026-07-29. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-08-07. Form 4, filed 2026-08-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-08-10. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-08-18. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-08-20. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-09-18. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-09-28. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-09-29. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-07. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-08. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-22. Form 4, filed 2026-10-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-23. Form 4, filed 2026-10-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Scully 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-15. Item 5.07 · say-on-pay result. As reported: 96.58% (votes for as printed: 32,303,076). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-19. Item 5.07 · say-on-pay result. As reported: 99.21% (votes for as printed: 45,196,711). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-20. Item 5.07 · say-on-pay result. As reported: 99.2%. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 639,315 + equity 0 + all other 6,500 = 645,815, summed across the director compensation table rows.
- Biohaven Ltd., Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven Ltd.'s own proxy. As printed: 13,500,438. View filing ↗
- Axsome, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome's own proxy. As printed: 10,283,492. View filing ↗
- Intra-Cellular, Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular's own proxy. As printed: 10,086,413. View filing ↗
- Arcus Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
- Sage Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. View filing ↗
- Prothena Corp Public Ltd Co (subject), Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Prothena Corp Public Ltd Co's own proxy. As printed: 5,896,045. View filing ↗
- Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
- Celldex Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. View filing ↗
- Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
- Neumora Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Neumora Therapeutics's own proxy. As printed: 4,562,461. View filing ↗
- Anavex Life Sciences, Section 10b CEO total. DEF 14A, filed 2026-08-11. CEO total compensation as printed in Anavex Life Sciences's own proxy. As printed: 3,959,085. View filing ↗
- Section 10a, Denali Therapeutics reciprocity. DEF 14A. Denali Therapeutics names Prothena Corp Public Ltd Co in its own disclosed peer group (read from its most recent proxy). View filing ↗